AVD-104

Aviceda Therapeutics, Inc. · Phase 2 active Small molecule

At a glance

Generic name	AVD-104
Sponsor	Aviceda Therapeutics, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) (PHASE2)
A Phase 2 Study of Intravitreal AVD-104 in Diabetic Macular Edema (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AVD-104 CI brief — competitive landscape report
AVD-104 updates RSS · CI watch RSS
Aviceda Therapeutics, Inc. portfolio CI